Ivabradine Teva Sante (Ivabradine Hydrochloride)

• Ivabradine is indicated for conditions where heart‑rate reduction improves clinical outcomes, primarily within the angina and heart‑failure disease families.
• Chronic stable angina pectoris: improves exercise tolerance and reduces the frequency of angina attacks.
• Heart failure with reduced ejection fraction: lowers heart rate, contributing to reduced hospitalisation risk in symptomatic patients.
• Patients intolerant to beta‑blockers: provides an alternative mechanism for heart‑rate control when beta‑blockers are not tolerated.

• Ivabradine selectively binds to the hyperpolarization‑activated cyclic nucleotide‑gated (HCN) channels that generate the funny (If) current in sinoatrial node cells. By inhibiting this inward Na⁺/K⁺ current, the drug slows spontaneous depolarisation, reducing the intrinsic heart rate without depressing myocardial contractility or blood pressure. The effect is dose‑dependent and reversible upon discontinuation, allowing clinicians to achieve heart‑rate control while preserving cardiac output, especially in patients unsuitable for negative‑inotropic agents.

Ivabradine may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Bradycardia: heart rate slower than intended.
• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache: mild to moderate intensity.
• Dizziness or vertigo: sensation of light‑headedness.
• Nausea: gastrointestinal upset.
• Fatigue: feeling of tiredness.

Serious or Rare Side Effects

• Severe bradycardia with symptomatic hypotension: may require medical intervention.
• Atrial fibrillation or other arrhythmias: new onset rhythm disturbances.
• Significant hepatic enzyme elevation: indicates possible liver injury.

• When prescribing Ivabradine, clinicians should observe several safety considerations to minimise risk.
• Heart‑rate monitoring: check baseline and periodic heart rate to avoid excessive bradycardia.
• Contraindication in severe hepatic impairment: avoid use in patients with marked liver dysfunction.
• Caution in sick sinus syndrome or atrioventricular block: assess conduction system before initiation.
• Avoid concomitant strong CYP3A4 inhibitors: may increase plasma levels and risk of toxicity.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Ivabradine interacts with several medicines that can alter its plasma concentration or additive physiological effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole): markedly increase ivabradine exposure, raising risk of bradycardia.
• Other heart‑rate‑lowering agents (beta‑blockers, digoxin, non‑DHP calcium channel blockers): may cause excessive bradycardia or atrioventricular block.
• Amiodarone: potent inhibitor of ivabradine metabolism, leading to heightened adverse effects.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise ivabradine levels; monitor heart rate.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce ivabradine efficacy; consider dose adjustment.
• Drugs that prolong QT interval (e.g., sotalol): combined effect may increase arrhythmia risk; monitor ECG.